Current Alzheimer Research - Volume 16, Issue 11, 2019

Memory impairment has been considered as one of the earliest clinical hallmarks of Alzheimer’s disease. This paper summarizes recent progress in the assessment of memory impairment in predementia stages. New promising approaches of memory assessment include evaluation of longitudinal cognitive changes, assessment of long-term memory loss, evaluation of subjective cognitive concerns and testing of other Read More

Background: Diabetes is considered as a risk factor for Alzheimer’s Disease, but it is yet unclear whether this pathological link is reciprocal. Although Alzheimer’s disease and diabetes appear as entirely different pathological entities affecting the Central Nervous System and a peripheral organ (pancreas), respectively, they share a common pathological core. Recent evidence suggests that in the pancreas in the case of di Read More

A combinatorial cocktail approach is suggested as a rationale intervention to attenuate chronic inflammation and confer neuroprotection in Alzheimer’s disease (AD). The requirement for an assemblage of pharmacological compounds follows from the host of pro-inflammatory pathways and mechanisms present in activated microglia in the disease process. This article suggests a starting point using four compounds which Read More

Background: Plasma clusterin has been reported to be associated with the pathology, prevalence, severity, and rapid clinical progress of Alzheimer’s Disease (AD). However, whether plasma clusterin can be used as a biomarker of AD is inconsistent and even conflicting. Objective: We conducted this study to evaluate the potential of plasma clusterin as the biomarker of AD. Method: PubMed, Embase, and Cochrane dat Read More

Background: Various methodologies have been employed for the therapeutic interpolation of the progressive brain disorder Alzheimer’s disease. Thus, β-secretase inhibition is significant to prevent disease progression in the early stages. Objective: This study seeks to purify and characterize a novel β-secretase inhibitory peptide from Pacific hake enzymatic hydrolysate. Methods: A potent β-secretase inhibitory peptide was isola Read More

Background: Lifetime exposure to environmental (neuro) toxicants may contribute to the pathogenesis of Alzheimer’s Disease (AD). Since many contaminants do not cross the blood-brain barrier, brain tissue alone cannot serve to assess the spectrum of environmental exposures. Methods: We used liquid and gas chromatography tandem mass spectrometry to monitor, in postmortem liver and adipose tissues of AD patients Read More

Introduction: We recently showed that Amyloid Beta (Aβ)40 accumulates in erythrocytes and possibly causes cell damage as evidenced by an increased number of assumed injured low-density (kg/L) erythrocytes. Furthermore, we have suggested a separation technique to isolate and concentrate such damaged red blood cells for subsequent analysis. Objectives: We isolated high- and low-density erythrocytes and inves Read More

Background: Visuospatial dysfunction is one predominant symptom in many atypical Alzheimer’s disease (AD) patients, however, until now its neural correlates still remain unclear. For the accumulation of intracellular hyperphosphorylated tau proteins is a major pathogenic factor in neurodegeneration of AD, the distributional pattern of tau could highlight the affected brain regions associated with specific cognitive de Read More

Background: Vitamin D insufficiency is associated with brain changes, and cognitive and mobility declines in older adults. Objective: Our objective was to investigate in older adults whether vitamin D insufficiency<50nmol/L was associated with thinner cingulate cortex, a brain area related to cognitive functions influenced by vitamin D. Methods: Two hundred and fifteen Caucasian older community-dwellers (mean±SD, 72.1±5. Read More